Versartis International Trial in Adults With Long-Acting Growth Hormone

Inclusion Criteria: * Female subjects of childbearing potential must have negative pregnancy test and use appropriate contraceptive methods * Subjects must have documented GHD during adulthood. * Subjects taking other hormone replacement therapy must have been on a stable course of treatment for at least 3 months. * Subjects with underlying disorders responsible for the subject's GHD must have been clinically stable for at least 6 months. * Subjects receiving daily rhGH injections must washout for 14 days. * Subjects must provide signed informed consent. * Subjects must have a BMI (kg/m2) between 19.0 and 35.0. Exclusion Criteria: * Subjects with diabetes mellitus or inadequate glucose control * Subjects with untreated adrenal insufficiency. * Subjects with free thyroxine outside the normal reference range. * Subjects currently taking oral glucocorticoids, except for physiological maintenance doses of oral glucocorticoids in subjects with multiple pituitary hormone deficiencies. * Subjects with current significant cardiovascular disease, heart insufficiency of NYHA class \> 2. * Subjects with current significant cerebrovascular, pulmonary, neurological, renal, inflammatory, or hepatobiliary disease. * Subjects with current papilledema. * Subjects with a history of persistent or recurring migraines. * Subjects with current edema (≥ CTCAE Grade 2). * Subjects with current drug or alcohol abuse. * Subjects with a documented history of HIV, current HBV or HCV infection * Subjects with a prior history of malignancy excluding adequately treated non-melanoma skin cancers or in situ carcinoma of the cervix. * Women who are pregnant or breastfeeding. * Subjects with a significant abnormality in Screening laboratory results